ImmunityBio Revenue Climbs 53% as Quarterly Loss Widens

ImmunityBio said Monday its third-quarter net product revenue rose 53% year over year, while its net loss widened and its ANKTIVA-plus-BCG regimen met the primary endpoint in a bladder cancer trial. Net product revenue reached $48.7 million in the quarter. For the first nine months of 2026, it totaled $143.6 million, up 92% from a year earlier. Cash, cash equivalents and marketable securities stood at $334.3 million on Sept. 30. Net loss attributable to common stockholders was $184.6 million, compared with $67.3 million in the year-earlier quarter. ImmunityBio attributed much of the increase to noncash fair-value changes in a related-party convertible note and warrant liabilities. Research and development expense rose to $71.5 million from $51.2 million. Selling, general and administrative expense increased to $54 million from $36.3 million.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.